[BADER, Benjamin, BÖMER, Ulf, INCE, Stuart, KOPPITZ, Marcus, LIENAU, Philip, MARQUARDT, Tobias, NGUYEN, Duy, PRECHTL, Stefan, SIEMEISTER, Gerhard, WEGSCHEID-GERLACH, Christof] Müllerstr. 178 13353 Berlin;Hillmannstrasse 14 13467 Berlin;Leipziger Str. 49 16548 Glienicke;Katteweg 27a 14129 Berlin;Scharnhorststr. 28 10115 Berlin;Pücklerstr. 33 10997 Berlin;Pfalzburger Str. 53, Garten 10717 Berlin;Heinrich-Heine-Strasse 27 10179 Berlin;Kanzowstr. 5A 10439 Berlin;Reimerswalder Steig 26 13503 Berlin;Salegrund 10 35041 Marburg The present invention relates to substituted aminoquinoxaline compounds of general formula (I) in which (II), R2, R3, R4, R6, R7, n and m are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

[KETTSCHAU, Georg, HARTUNG, Ingo, LÜCKING, Ulrich, THIERAUCH, Karl-Heinz, BRIEM, Hans, BÖMER, Ulf, KRUEGER, Martin] Müllerstrasse 178 13353 Berlin;Mendelstrasse 41 13187 Berlin;Wittenauer Strasse 127 13469 Berlin;Bödikerstrasse 6 10245 Berlin;Hochwildpfad 45 14169 Berlin;Baumhauser Weg 41 a 28279 Bremen;Leipziger Strasse 49 16548 Glienicke/Nordbahn;Heeruferweg 7A 13465 Berlin The invention relates to substituted sulphoximines according to the general formula (I):in which A, E, G, X, R1, R2 , R3, R4, R5, R6, R7, R8, m, p, q, are given in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted sulphoximines, to methods of preparing said substituted sulphoximines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

[Ulrich Lücking, Dirk Kosemund, Arne Scholz, Philip Lienau, Gerhard Siemeister, Ulf Bömer, Rolf Bohlmann] DE Berlin The present invention relates to disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

[BOTHE, Ulrich, VON BONIN, Arne, NGUYEN, Duy, BÖMER, Ulf, GUENTHER, Judith] Müllerstr. 178 13353 Berlin;Kavalierstr. 15 13187 Berlin;Rosa-Luxemburg-Str. 6 a 16548 Glienicke-Nordbahn;Heinrich-Heine-Str. 27 10179 Berlin;Leipziger Strasse 49 16548 Glienicke;Parkstr. 60 13187 Berlin The invention relates to 2-substituted thiazole-4-carboxamide derivatives of formula (I), the use thereof as a medicament for treating various diseases, and methods for the production thereof.

[SCHWARZ, Siegfried, KOSEMUND, Dirk, MÜLLER, Gerd, RICHTER, Margit, PETERS, Olaf, DROESCHER, Peter, ELGER, Walter, HILLISCH, Alexander, BÖMER, Ulf, FRITZEMEIER, Karl-Heinrich, HEGELE-HARTUNG, Christa] Patentabteilung Müllerstrasse 178 D-1335 Berlin;Ottogerd-Mülmann-Strasse 17 D-07743 Jena;Ulan-Bator-Strasse 51 D-99091 Erfurt;Magdelstieg 132 D-07745 Jena;Magdelstieg 117b D-07745 Jena;Am Birnstiel 22 D-07745 Jena;Lessingstrasse 7 D-99425 Weimar;Schorlemmerallee 12b D-14195 Berlin;Lutherstrasse 84 D-07745 Jena;Neue Nochstrasse 11 D-13347 Berlin;Rabenstrasse 5a D-13505 Berlin;Woellenbeck 101 D-45470 Mülheim an der Ruhr This invention describes the new ent-steroids of general formula (I) in which R?1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R19¿ have the meanings that are indicated in the description, as pharmaceutical active ingredients that in vitro have a higher affinity to estrogen receptor preparations of rat prostates than to estrogen receptor preparations from rat uteri and in vivo preferably a preferential action on bone rather than the uterus and/or pronounced action with respect to stimulation of the expression of 5HT2a-receptors and transporters, their production, their therapeutic use and pharmaceutical forms for dispensing, which contain the new compounds. The invention also describes the use of steroids, on which the (8α-H, 9β-H, 10α-H, 13α-H, 14β-H)-gonane skeleton is based, for treatment of estrogen-deficiency-induced diseases and conditions.

[ORSI, Douglas, WAGNER, Florence, F., CORSELLO, Steven, SHEKHAR, Mrinal, HANDING, Katarzyna, FERRARA, Steven, James, MCKINNEY, David, SCHULZE, Volker, MENGEL, Anne, LEMOS, Clara, CHRISTIAN, Sven, BÖMER, Ulf, HILLIG, Roman, LECHNER, Christian, MORTIER, Jérémie, KAULFUSS, Stefan, BERGER, Markus, RUPAIMOOLE, Rajesha, LIENAU, Philip, BRZEZINKA, Krzysztof] 415 Main Street, Cambridge, MA 02142, US

[EIS, Knut, PÜHLER, Florian, ZORN, Ludwig, SCHOLZ, Arne, LIENAU, Philip, GNOTH, Mark, Jean, BÖMER, Ulf, GÜNTHER, Judith, FANGHÄNEL, Jörg, KORR, Daniel] Alfred-Nobel-Str. 10 40789 Monheim;Fichtenweg 1 13587 Berlin;Jules-Verne-Str. 50 14089 Berlin;Osiandenweg 45a 13509 Berlin;Schönhauser Allee 170 10435 Berlin;Jahnstr. 13 10967 Berlin;Am Hang 53 40822 Mettmann;Leipziger Str. 49 16548 Glienicke/Nordbahn;Parkstr. 60 13187 Berlin;c/o Fortune Plaza No. 7, 16th Floor, Dong San Huan Zhong Road Peking, 100020;Hufelandstr. 45a 10407 Berlin The present invention relates to heterocyclyl aminoimidazopyridazine compounds of general formula (I) : in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper- proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

[KÜNZER, Hermann, KNAUTHE, Rudolf, LESSL, Monika, FRITZEMEIER, Karl-Heinrich, HEGELE-HARTUNG, Christa, BÖMER, Ulf, MÜLLER, Gerd, KOSEMUND, Dirk] Müllerstr. 178 D-13353 Berlin;Turiner Str. 4 D-13347 Berlin;Wilhelmstr. 9 D-13467 Berlin;Wilhelmstr. 9 D-13467 Berlin;Rabenstr. 5 A D-13505 Berlin;Woellenbeck 101 D-45740 Mülheim a. d. Ruhr;Neue Hochstr. 11 D-13347 Berlin;Magdelstieg 132 D-07745 Jena;Ulan-Bator-Str. 51 D-99091 Erfurt The invention relates to novel compounds as pharmaceutical agents which have in vitro a higher affinity to estrogen receptor preparations of the rat prostate than to estrogen receptor preparations of the rat uterus and which preferably have in vivo a preferential effect on bones as compared to the uterus and/or a marked effect with regard to the stimulation of the expression of the 5HT2a receptor and transporter. The invention also relates to the production and to the use in therapy of these compounds and to pharmaceutical administration forms containing said novel compounds. The novel compounds are 16α and 16β hydroxy-estra,1,3,5(10)-estratriene which carry additional substituents at the steroid backbone and one or more additional double bonds on the B, C and/or D rings.

[Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bömer, Dirk Kosemund, Philip Lienau, Gerd Rühter, Carsten Schultz-Fademrecht] DE Berlin The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).

[Knut Eis, Florian Pühler, Ludwig Zorn, Arne Scholz, Philip Lienau, Mark Jean Gnoth, Ulf Bömer, Judith Günther, Jörg Fanghänel, Daniel Korr] DE Berlin The present invention relates to substituted aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.